In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey

Figen Sarigöl Yildirim; Ulkö User; Nagehan Didem Sari; Behice Kurtaran; Yusuf Önlen; Ebubekir Senates; Alper Göndöz; Esra Zerdali; Hasan Karsen; Ayse Batirel; Ridvan Karaali; Rahmet Göner; Tansu Yamazhan; Sökran Köse; Nurettin Erben; Nevin Ince; Iftihar Köksal; Nefise Cuvalci Öztoprak; Gölsen Yörök; Söheyla Kömör; Tayibe Bal; Sibel Kaya; Ilkay Bozkurt; Özgör Gönal; Ilknur Esen Yildiz; Dilara Inan; Sener Barut; Mustafa Namiduru; Selma Tosun; Kamuran Törker; Alper Sener; Kenan Hizel; Nurcan Baykam; Fazilet Duygu; Hörrem Bodur; Göray Can; Hanefi Cem Göl; Ayse Sagmak Tartar; Göven Celebi; Mahmut Sönnetcioglu; Oguz Karabay; Hayat Kumbasar Karaosmanoglu; Fatma Sirmatel; Fehmi Tabak

doi:10.5152/tjg.2022.21834

In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey

Figen Sarigöl Yildirim
, Ulkö User
, Nagehan Didem Sari
, Behice Kurtaran
, Yusuf Önlen
, Ebubekir Senates
, Alper Göndöz
, Esra Zerdali
, Hasan Karsen
, Ayse Batirel
, Ridvan Karaali
, Rahmet Göner
, Tansu Yamazhan
, Sökran Köse
, Nurettin Erben
, Nevin Ince
, Iftihar Köksal
, Nefise Cuvalci Öztoprak
, Gölsen Yörök
, Söheyla Kömör

Tayibe Bal, Sibel Kaya, Ilkay Bozkurt, Özgör Gönal, Ilknur Esen Yildiz, Dilara Inan, Sener Barut, Mustafa Namiduru, Selma Tosun, Kamuran Törker, Alper Sener, Kenan Hizel, Nurcan Baykam, Fazilet Duygu, Hörrem Bodur, Göray Can, Hanefi Cem Göl, Ayse Sagmak Tartar, Göven Celebi, Mahmut Sönnetcioglu, Oguz Karabay, Hayat Kumbasar Karaosmanoglu, Fatma Sirmatel, Fehmi Tabak

Antalya Training and Research Hospital
Istanbul Education Research Hospital
Cukurova University
Mustafa Kemal University
Ministry of Health, Turkey
Istanbul Sili Hamidiye Etfal Training and Research Hospital
Haseki Education Research Hospital
Harran University
Istanbul Doctor Lötfi Krdar Kartal Training and Research Hospital
Namk Kemal University Faculty of Medicine
Ankara Yldrm Beyazt University Faculty of Medicine
Ege University
Izmir Tepecik Training and Research Hospital
Osmangazi University
Duzce University
Karadeniz Technical University
Istanbul University - Cerrahpaşa
Ondokuz Mayis University
Samsun Education Research Hospital
Recep Tayyip Erdogan University
Akdeniz University
Gaziosmanpasa University
Gaziantep University
Istanbul Baclar Training and Research Hospital
Canakkale Onsekiz Mart University
Gazi University
Hitit University
Ankara Oncology Education and Research Hospital
Ankara Numune Education and Research Hospital
Abant Izzet Baysal University
University of Health Sciences
Firat University
Zonguldak Bülent Ecevit University
Yuzuncu Yil University
Sakarya University

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Background: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-Acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. Methods: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-Acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: Direct-Acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization s objective of eliminating viral hepatitis.

Original language	English
Pages (from-to)	971-978
Number of pages	8
Journal	Turkish Journal of Gastroenterology
Volume	33
Issue number	11
DOIs	https://doi.org/10.5152/tjg.2022.21834
Publication status	Published - 1 Nov 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Drug therapy
drug users
hepatitis C virus

Access to Document

10.5152/tjg.2022.21834

Cite this

Yildirim, F. S., User, U., Sari, N. D., Kurtaran, B., Önlen, Y., Senates, E., Göndöz, A., Zerdali, E., Karsen, H., Batirel, A., Karaali, R., Göner, R., Yamazhan, T., Köse, S., Erben, N., Ince, N., Köksal, I., Öztoprak, N. C., Yörök, G., ... Tabak, F. (2022). In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey. Turkish Journal of Gastroenterology, 33(11), 971-978. https://doi.org/10.5152/tjg.2022.21834

@article{5395ceace1a841c2b53531259950657e,

title = "In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey",

abstract = "Background: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-Acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. Methods: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-Acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4\% vs 9.9\% and 46.8\% vs 5.3\%). The number of na{\"i}ve patients was higher in PWID (90.7\% vs 60.0\%), while the number of patients with cirrhosis was higher in non-PWID (14.1\% vs 3.7\%). The loss of follow-up was higher in PWID (29.6\% vs 13.6\%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3\% vs 98.4\%), but the end of treatment response was lower in PWID (96.2\% vs 99.0\%). In addition, the rate of treatment completion was lower in PWID (74\% vs 94.4\%). Conclusion: Direct-Acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization s objective of eliminating viral hepatitis.",

keywords = "Drug therapy, drug users, hepatitis C virus",

author = "Yildirim, \{Figen Sarig{\"o}l\} and Ulk{\"o} User and Sari, \{Nagehan Didem\} and Behice Kurtaran and Yusuf {\"O}nlen and Ebubekir Senates and Alper G{\"o}nd{\"o}z and Esra Zerdali and Hasan Karsen and Ayse Batirel and Ridvan Karaali and Rahmet G{\"o}ner and Tansu Yamazhan and S{\"o}kran K{\"o}se and Nurettin Erben and Nevin Ince and Iftihar K{\"o}ksal and {\"O}ztoprak, \{Nefise Cuvalci\} and G{\"o}lsen Y{\"o}r{\"o}k and S{\"o}heyla K{\"o}m{\"o}r and Tayibe Bal and Sibel Kaya and Ilkay Bozkurt and {\"O}zg{\"o}r G{\"o}nal and Yildiz, \{Ilknur Esen\} and Dilara Inan and Sener Barut and Mustafa Namiduru and Selma Tosun and Kamuran T{\"o}rker and Alper Sener and Kenan Hizel and Nurcan Baykam and Fazilet Duygu and H{\"o}rrem Bodur and G{\"o}ray Can and G{\"o}l, \{Hanefi Cem\} and Tartar, \{Ayse Sagmak\} and G{\"o}ven Celebi and Mahmut S{\"o}nnetcioglu and Oguz Karabay and Karaosmanoglu, \{Hayat Kumbasar\} and Fatma Sirmatel and Fehmi Tabak",

year = "2022",

month = nov,

day = "1",

doi = "10.5152/tjg.2022.21834",

language = "English",

volume = "33",

pages = "971--978",

journal = "Turkish Journal of Gastroenterology",

issn = "1300-4948",

publisher = "AVES",

number = "11",

}

Yildirim, FS, User, U, Sari, ND, Kurtaran, B, Önlen, Y, Senates, E, Göndöz, A, Zerdali, E, Karsen, H, Batirel, A, Karaali, R, Göner, R, Yamazhan, T, Köse, S, Erben, N, Ince, N, Köksal, I, Öztoprak, NC, Yörök, G, Kömör, S, Bal, T, Kaya, S, Bozkurt, I, Gönal, Ö, Yildiz, IE, Inan, D, Barut, S, Namiduru, M, Tosun, S, Törker, K, Sener, A, Hizel, K, Baykam, N, Duygu, F, Bodur, H, Can, G, Göl, HC, Tartar, AS, Celebi, G, Sönnetcioglu, M, Karabay, O, Karaosmanoglu, HK, Sirmatel, F & Tabak, F 2022, 'In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey', Turkish Journal of Gastroenterology, vol. 33, no. 11, pp. 971-978. https://doi.org/10.5152/tjg.2022.21834

TY - JOUR

T1 - In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey

AU - Yildirim, Figen Sarigöl

AU - User, Ulkö

AU - Sari, Nagehan Didem

AU - Kurtaran, Behice

AU - Önlen, Yusuf

AU - Senates, Ebubekir

AU - Göndöz, Alper

AU - Zerdali, Esra

AU - Karsen, Hasan

AU - Batirel, Ayse

AU - Karaali, Ridvan

AU - Göner, Rahmet

AU - Yamazhan, Tansu

AU - Köse, Sökran

AU - Erben, Nurettin

AU - Ince, Nevin

AU - Köksal, Iftihar

AU - Öztoprak, Nefise Cuvalci

AU - Yörök, Gölsen

AU - Kömör, Söheyla

AU - Bal, Tayibe

AU - Kaya, Sibel

AU - Bozkurt, Ilkay

AU - Gönal, Özgör

AU - Yildiz, Ilknur Esen

AU - Inan, Dilara

AU - Barut, Sener

AU - Namiduru, Mustafa

AU - Tosun, Selma

AU - Törker, Kamuran

AU - Sener, Alper

AU - Hizel, Kenan

AU - Baykam, Nurcan

AU - Duygu, Fazilet

AU - Bodur, Hörrem

AU - Can, Göray

AU - Göl, Hanefi Cem

AU - Tartar, Ayse Sagmak

AU - Celebi, Göven

AU - Sönnetcioglu, Mahmut

AU - Karabay, Oguz

AU - Karaosmanoglu, Hayat Kumbasar

AU - Sirmatel, Fatma

AU - Tabak, Fehmi

PY - 2022/11/1

Y1 - 2022/11/1

N2 - Background: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-Acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. Methods: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-Acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: Direct-Acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization s objective of eliminating viral hepatitis.

AB - Background: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-Acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. Methods: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-Acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: Direct-Acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization s objective of eliminating viral hepatitis.

KW - Drug therapy

KW - drug users

KW - hepatitis C virus

U2 - 10.5152/tjg.2022.21834

DO - 10.5152/tjg.2022.21834

M3 - Article

SN - 1300-4948

VL - 33

SP - 971

EP - 978

JO - Turkish Journal of Gastroenterology

JF - Turkish Journal of Gastroenterology

IS - 11

ER -

In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this